CA71716W1059
© Newsfile
05.01.2026
PHRX
LISTED
CSE
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
News Preview
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 3...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2025
PHRX
LISTED
CSE
PharmaDrug Announces Debt Restructuring
News Preview
Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2025
PHRX
LISTED
CSE
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
News Preview
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definit...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
30.07.2025
PHRX
LISTED
CSE
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
News Preview
Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), announces that the original news release captioned "PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc." published on July 30, 2025 referred, incorrectly, to the number of common shares of PharmaDrug to be...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
30.07.2025
PHRX
LISTED
CSE
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
News Preview
Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is announcing that it has entered into a non-binding Letter of Intent ("LOI") on July 23rd, 2025 to acq...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2025
PHRX
LISTED
CSE
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
News Preview
Toronto, Ontario--(Newsfile Corp. - June 16, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that Rob St...
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2025
PHRX
LISTED
CSE
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
News Preview
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that the boa...
Themefolio
Profiler
Peergroup
© Newsfile
15.11.2024
PHRX
LISTED
CSE
PharmaDrug Announces Issuance of Debenture Units
News Preview
Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and naturally-derived approved drugs, is pleased to announce that further...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2024
PHRX
LISTED
CSE
PharmaDrug Announces Proposed Issuance of Debenture Units
News Preview
Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to a...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
News Preview
Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing it has s...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
News Preview
Toronto, Ontario--(Newsfile Corp. - September 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing it has...
Themefolio
Profiler
Peergroup
© Newsfile
28.08.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
News Preview
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce its s...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
21.08.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
News Preview
Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce...
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
News Preview
Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce...
Themefolio
Profiler
Peergroup
© Newsfile
23.05.2024
PHRX
LISTED
CSE
Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
News Preview
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
News Preview
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce tha...
Themefolio
Profiler
Peergroup
© Newsfile
13.05.2024
PHRX
LISTED
CSE
PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
News Preview
Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs is pleased to provide a Corporate update from CEO,...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2024
PHRX
LISTED
CSE
PharmaDrug Announces Director Appointment and Resignation
News Preview
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce toda...
Themefolio
Profiler
Peergroup
© Newsfile
01.05.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
News Preview
Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that...
Themefolio
Profiler
Peergroup
© Newsfile
16.04.2024
PHRX
LISTED
CSE
PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
News Preview
Victoria's Chiral Labs to lead development of novel cocaine manufacturing processToronto, Ontario--(Newsfile Corp. - April 16, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicine...
Themefolio
Profiler
Peergroup
© Newsfile
13.03.2024
PHRX
LISTED
CSE
PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
News Preview
Toronto, Ontario--(Newsfile Corp. - March 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that it has initiated wo...
Themefolio
Profiler
Peergroup
© Newsfile
27.02.2024
PHRX
LISTED
CSE
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
News Preview
Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announc...
Themefolio
Profiler
Peergroup
© Newsfile
14.02.2024
PHRX
LISTED
CSE
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
News Preview
Company to pursue regulatory filing for Phase I/II clinical studyToronto, Ontario--(Newsfile Corp. - February 14, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as...
Themefolio
Profiler
Peergroup
© Newsfile
12.02.2024
PHRX
LISTED
CSE
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
News Preview
Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), today announced that it has entered into (i) a marketing and distribution services agreement (the "OTB Agreement") with an arm's length marketing firm, Outside The Box Capital Inc. ("OTBC") to provide marketing ser...
Themefolio
Profiler
Peergroup
© Newsfile
08.02.2024
PHRX
LISTED
CSE
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce the closing of its previously announced non-brokered private placement raising total gross proceeds of $326,000 (the "Offering").Pursuant to the Offering the Company issued 6,520,000 units ("U...
Themefolio
Profiler
Peergroup
© Newsfile
01.02.2024
PHRX
LISTED
CSE
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce a proposed non-brokered private placement offering of units ("Units") to raise total gross proceeds of up to $326,000 (the "Offering").Pursuant to the Offering the Company will issue up to 6,5...
Themefolio
Profiler
Peergroup
© Newsfile
13.12.2023
PHRX
LISTED
CSE
PharmaDrug CEO Provides Vision for Securedose Acquisition
News Preview
Toronto, Ontario--(Newsfile Corp. - December 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is providing an updat...
Themefolio
Profiler
Peergroup
© Newsfile
15.11.2023
PHRX
LISTED
CSE
PharmaDrug Inc. Completes Debt Restructuring
News Preview
Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announced debt restructuring (see press release dated November 7, 2023). Under the restructuring, the Company agreed with the holders of its unsecured conver...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2023
PHRX
LISTED
CSE
PharmaDrug Inc. Announces Grant of Stock Options
News Preview
Toronto, Ontario--(Newsfile Corp. - November 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), announces that it has granted a total of 6,250,000 stock options ("Options") to purchase common shares of the Company to certain officers, directors and consultants pursuant to the Company's Stock Option Plan. Such...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2023
PHRX
LISTED
CSE
PharmaDrug Inc. Closes Acqusition of Securedose Synthetics
News Preview
Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27, 2023) of Securedose Synthetics Inc. ("SecureDose"). PharmaDrug acquired all of the issued and outst...
Themefolio
Profiler
Peergroup
© Newsfile
27.10.2023
PHRX
LISTED
CSE
PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
News Preview
Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into a definitive agreement (the "Acquisition Agreement") dated October 27, 2023 pursuant to which PharmaDrug will acquire all of the issued and outstanding shares of priva...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2023
PHRX
LISTED
CSE
PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
News Preview
Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it will be proceeding with the consolidation of its common shares (the "Common Shares") on the basis of seven (7) pre consolidated Common Shares into one (1) post consolidated Common Share (the "Sh...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2023
PHRX
LISTED
CSE
PharmaDrug Announces Amendment to Shareholder Meeting Matter
News Preview
Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director of the Company at the upcoming annual and special meeting of the Company...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2023
PHRX
LISTED
CSE
PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
News Preview
Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to provide an update on the development activities of the Company's patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infe...
Themefolio
Profiler
Peergroup
© Newsfile
06.09.2023
PHRX
LISTED
CSE
PharmaDrug Announces Appointment of CEO and Changes to the Board of Directors
News Preview
Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today the appointment of Robert J. Steen as Chief Executive Officer (CEO) and Chairman of the Board of Directors. Robert will replace Daniel Cohen, who will continue on in an advisory capacity to ensure a pr...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2023
PHRX
LISTED
CSE
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
News Preview
Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement yesterday with PharmaTher Inc. ("PharmaTher"), a wholly-owned subsidiary of PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF), pursuant to which PharmaTher will subscribe...
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2023
PHRX
LISTED
CSE
PharmaDrug Announces Termination of General Security Agreement and Issuance of Common Shares
News Preview
Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement with the holders of $650,000 principal amount of the Company's convertible debentures to terminate a general security agreement granted by the Company's wholly-owned subsidi...
Themefolio
Profiler
Peergroup
© Newsfile
23.05.2023
PHRX
LISTED
CSE
PharmaDrug Brings On Advisor to Maximize Shareholder Value With Its Underlying Assets
News Preview
Toronto, Ontario--(Newsfile Corp. - May 23, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that it has appointed David Posner to its Advisory Committee and as a consultant with a mandate for strategic initiatives and corporate restructuring. Daniel Cohen, Chairman and CEO of PharmaDrug commented, "...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2023
PHRX
LISTED
CSE
PharmaDrug Announces Cease Trade Order
News Preview
Toronto, Ontario--(Newsfile Corp. - May 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that the Ontario Securities Commission has issued a "failure to file" cease trade order in respect of the Company's securities under Multilateral Instrument 11-103 Failure-to- File Cease Trade Orders in Multip...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2023
PHRX
LISTED
CSE
PharmaDrug Announces Non-Brokered Offering of $100,000 of Convertible Secured Debentures
News Preview
Toronto, Ontario--(Newsfile Corp. - April 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announ...
Themefolio
Profiler
Peergroup
© Newsfile
22.02.2023
PHRX
LISTED
CSE
PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch
News Preview
PharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neuropsychiatric conditionsToronto, Ontario--(Newsfile Corp. - February 22, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of...
Themefolio
Profiler
Peergroup
© Newsfile
13.02.2023
PHRX
LISTED
CSE
PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer
News Preview
Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company intends to pursue a fir...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2023
PHRX
LISTED
CSE
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer
News Preview
Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has completed filing a P...
Themefolio
Profiler
Peergroup
© Newsfile
04.10.2022
PHRX
LISTED
CSE
PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
News Preview
Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substanceOptimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND filing and clinical requirementsToronto, Ontario--(Newsfile Corp. - October 4, 2022)...
Themefolio
Profiler
Peergroup
© Newsfile
25.08.2022
PHRX
LISTED
CSE
PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
News Preview
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022PharmaDrug extends contract with investigators at Johns Hopkins University in support of forthcoming (Q4, 2022) FDA IND Application for a Phase 1 clinical stud...
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2022
PHRX
LISTED
CSE
PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease
News Preview
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substanceClinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in second half of September 2022Genvion Corporation formally engaged to conduct ICH-compliant stability, forced degradation and d...
Themefolio
Profiler
Peergroup
© Newsfile
03.08.2022
PHRX
LISTED
CSE
Pharmadrug Announces Closing of Sale of German Cannabis Assets
News Preview
Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("Pharmadrug" or the "Company"), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities of Pharmadrug Production GmbH ("Pharmadrug GmbH") to Khiron L...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2022
PHRX
LISTED
CSE
PharmaDrug Announces Non-Brokered Offering of $650,000 of Convertible Secured Debentures and Issuances of Common Shares
News Preview
Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announ...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2022
PHRX
LISTED
CSE
PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study
News Preview
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049)Dose range finding demonstrates that oral cepharanthine-alone was well tolerated in the current in vivo study Toronto, Ontario--...
Themefolio
Profiler
Peergroup
© Newsfile
31.05.2022
PHRX
LISTED
CSE
PharmaDrug Announces Execution Of an Agreement to Sell Its German Cannabis Asset to Khiron
News Preview
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron") to sell all of the outstanding securities of Pharmadrug Production GmbH, ("Pharmadrug GMB...
Themefolio
Profiler
Peergroup
© Newsfile
27.05.2022
PHRX
LISTED
CSE
PharmaDrug Announces Closing of the First Tranche of Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - May 27, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased t...
Themefolio
Profiler
Peergroup
© Newsfile
03.05.2022
PHRX
LISTED
CSE
Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for Glaucoma
News Preview
Selection of lead candidate from initial short-list of 6 DMT-analoguesLead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range Results to be leveraged...
Themefolio
Profiler
Peergroup
© Newsfile
19.04.2022
PHRX
LISTED
CSE
PharmaDrug Advances Oncology Program with Filing of Provisional Patent Following Positive Findings for the Combination of PD-001 and Frontline Chemotherapy in Prostate Cancer Study
News Preview
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancerFinal study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor volume and increased tumor growth inhibitionDose range finding demonstrates t...
Themefolio
Profiler
Peergroup
© Newsfile
07.04.2022
PHRX
LISTED
CSE
PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure
News Preview
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate moleculesBiocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range Current results provide...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2022
PHRX
LISTED
CSE
Pharmadrug Advances PD-001, Its Patented, Improved Version of Cepharanthine for Oncology and Infectious Disease
News Preview
Committed to the 'pipeline-in-a-pill' approach with PD-001 for certain cancers and COVID-19Advances cGMP manufacturing of clinical drug supply with Southwest Research InstituteReceives final positive data for recently conducted prostate cancer model and evaluates opportunities to broaden claim set for PD-001 in the treatment of cancerInitiates IND-...
Themefolio
Profiler
Peergroup
© Newsfile
09.03.2022
PHRX
LISTED
CSE
PharmaDrug Announces Interim Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Prostate Cancer Study
News Preview
Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of dosingDose range findings demonstrate that oral cepharanthine-alone was well tolerated in the current in vivo study Results for oral cepharanthine plus cabazitaxel w...
Themefolio
Profiler
Peergroup
© Newsfile
23.02.2022
PHRX
LISTED
CSE
PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
News Preview
PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucomaTerasaki Institute advances PharmaDrug's candidate DMT-analogue molecules into next phase of potency/kinetics study Terasaki Institute initiates fabrication of novel medical device designed to deliver PharmaDrug's lead cand...
Themefolio
Profiler
Peergroup
© Newsfile
01.02.2022
PHRX
LISTED
CSE
PharmaDrug Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer
News Preview
Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancerExpands on Company's 'pipeline in a pill' strategy with cepharanthine in treating rare cancersToronto, Ontario--(Newsfile Corp. - February 1, 2022) - Pharma...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2022
PHRX
LISTED
CSE
PharmaDrug Announces Initiation of Manufacturing of Cepharanthine (PD-001) For Clinical Programs in Rare Cancers And COVID-19
News Preview
Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19Toronto, Ontario--(Newsfile Corp. - January 26, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, de...
Themefolio
Profiler
Peergroup
© Newsfile
24.01.2022
PHRX
LISTED
CSE
PharmaDrug to Present at Wall Street Reporter's "Next Super Stock" Livestream Conference on Tuesday January 25, 2022
News Preview
Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is ple...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
